Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Titlesort descending Type $ Amount Activity Investigator Unit Sponsor Date
A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-cell Lymphoma (PTCL) in Adults Age 60 and Above Contract $147,691.00 Clinical Trial Daniel Persky Cancer Center Division Seattle Genetics, Incorporated 05/2020
A Phase 2 Randomized Study of Adjuvant Immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma Contract $206,150.52 Clinical Trial Montaser Shaheen Cancer Center Division PPD Investigator Services, LLC. 10/2020
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated... Contract $55,928.00 Clinical Trial Chian Kwoh Arthritis Center-Research Cumberland Pharmaceuticals, Incorporated 07/2020
A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers Contract $226,383.60 Clinical Trial Aaron Scott Cancer Center Division Apexigen 04/2021
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor Contract $168,606.16 Clinical Trial Ricklie Julian Cancer Center Division Labcorp Drug Development Inc. 10/2021
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Contract $1,354,476.50 Clinical Trial Alejandro Recio Boiles Cancer Center Division Mirati Therapeutics, Inc. 03/2021
A Phase 2 Study to Evaluate the Sensitivity and Specificity of DBV1605, a Ready to Use Atopy Patch Test for the Diagnosis of Non-Immunoglobulin E Mediated Cow's Milk Allergy in Children Contract $683,487.50 Clinical Trial Heather Cassell Asthma/Airway Disease Rsch Ctr Covance, Incorporated 04/2021
A Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients with Respiratory Distress due to COVID-19.... Contract $484,131.00 Research Marilyn Glassberg Csete COM Phx Internal Medicine United States Biotest Incorporated 07/2021
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... Contract $273,767.50 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Janssen Research & Development, LLC 01/2020
A Phase 2, Double-blind, Randomized, Placebocontrolled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension( Contract $2,048,686.48 Clinical Trial Franz Rischard Medicine Acceleron Pharmaceuticals 04/2022
A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-3 Contract $80,418.76 Clinical Trial Franz Rischard Medicine Complexa, Inc. 01/2020
A Phase 2, Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination with Intravenous Pembrolizumab Therapy with or without Chemotherapy in Patients Contract $139,240.40 Clinical Trial Sima Ehsani Chimeh Cancer Center Division OncoSec Medical Incorporated 02/2022
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine in Participants Undergoing Surgeries that Include a Bowel Resection or Bowel Transection Contract $586,018.76 Clinical Trial Bellal Joseph Surgery Shionogi Inc 10/2020
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced or... Contract $336,093.00 Clinical Trial Rachna Shroff Cancer Center Division IMV Inc. (Canada) 03/2021
A Phase 2, Open-Label, Randomized, Two-Stage Clinical Study of Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax Combination Therapy Contract $19,626.00 Clinical Trial Ravitharan Krishnadasan Cancer Center Division IQVIA RDS Inc. 04/2021
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. Contract $171,440.00 Clinical Trial Aaron Scott Cancer Center Division Incyte Corporation 05/2020
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Contract $79,672.00 Clinical Trial Ramachandra Sista COM Phx Internal Medicine Vertex Pharmaceuticals, Incorporated 05/2020
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects Contract $165,904.00 Clinical Trial Ramachandra Sista COM Phx Internal Medicine Vertex Pharmaceuticals, Incorporated 03/2021
A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naive, HER2-Positive G Contract $194,029.06 Clinical Trial Aaron Scott Cancer Center Division MacroGenics Inc 07/2021
A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab +/- Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metas Contract $404,272.70 Clinical Trial Aaron Scott Cancer Center Division Leap Therapeutics, Inc. 10/2020
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fib Contract $640,083.00 Clinical Trial Geoffrey Block Liver Research Institute Zydus Pharmaceuticals (USA) Inc. 11/2021
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcino Contract $337,055.00 Clinical Trial Aaron Scott Cancer Center Division Incyte Corporation 04/2021
A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older Contract $484,469.00 Clinical Trial Cori Daines Asthma/Airway Disease Rsch Ctr Vertex Pharmaceuticals, Incorporated 02/2022
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib Contract $28,800.00 Clinical Trial Holly Pariury Cancer Center Division Public Health Institute 05/2022
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients... Contract $28,800.00 Clinical Trial Holly Pariury Cancer Center Division Children's Hospital of Philadelphia 06/2021

Pages